Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares
June 25, 2018 07:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 25, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing...
Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference
June 14, 2018 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 14, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) announced today that it will be presenting at the JMP Securities 2018 Life Sciences Conference on...
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering
May 29, 2018 16:57 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 29, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”) announced today the closing of its initial public offering of 8,477,777 Class A common...
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering
May 23, 2018 21:13 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 23, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (“Kiniksa”) announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a...